Investor Relations

Investor Overview Image

Prothena Corporation plc (Nasdaq: PRTA) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel antibodies that are directed towards diseases that involve protein misfolding or cell adhesion. These potential therapies have a number of indications including AL and AA forms of amyloidosis (NEOD001), Parkinson’s disease and related synucleinopathies (PRX002), and novel cell adhesion targets involved in autoimmune diseases and cancers (PRX003).

NASDAQ: PRTA
$ 18.09
0.72 (4.15%)

Day High: 18.38
Day Low:  17.50
Volume:    54,200
10:29 AM ET
Jul 29, 2014

Delayed ~20 min., by eSignal.

Press Releases

Jun 25, 2014
Jun 23, 2014